In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bending To Overwhelming Feedback, CMS Softens Stance On PET For Solid Tumors

This article was originally published in The Gray Sheet

Executive Summary

In a final decision memo released June 11, the Medicare agency provides national coverage for three post-cancer-treatment PET scans. The original coverage proposal would have allowed only one.

You may also be interested in...



CMS Unconvinced On PET Scans For Bone Metastasis; CED Data Not Enough

While National Oncologic PET Registry data has been effective in persuading CMS to remove evidence-development restrictions from positron emission tomography coverage policies in the past, NOPR data was not enough to support coverage of PET scans to identify bone metastasis in a Dec. 15 national coverage determination.

Alzheimer’s Community Prepares To Challenge CMS PET Proposal

Alzheimer’s researchers are planning to join with industry in a unified response to a Medicare coverage proposal that would, in their view, disastrously constrain use of positron emission tomography, and imaging agents like Eli Lilly’s Amyvid, in the diagnosis and management of Alzheimer’s patients.

Alzheimer’s Community Prepares To Challenge CMS Amyvid Proposal

Alzheimer’s community stakeholders are planning a unified response to a CMS Medicare coverage proposal that would, in their view, disastrously constrain use of PET imaging, and imaging agents like Lilly’s Amyvid, in the diagnosis and management of Alzheimer’s patients.

Related Content

Topics

UsernamePublicRestriction

Register

WI964842

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel